BAUDETTE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences as follows:
Truist Securities BioPharma Symposium (1x1s Only)
Date: | Thursday, November 9, 2023 |
To schedule a 1x1 meeting with management, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
Jefferies London Healthcare Conference
Date: | Wednesday, November 15, 2023 | |
Time: | 10:00am ET / 3:00pm GMT | |
Webcast: | Click here |
To schedule a 1x1 meeting with the Company, for November 14 or November 15, please contact Isabel Zakoscielny This email address is being protected from spambots. You need JavaScript enabled to view it..
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$65.07 |
Daily Change: | 0.16 0.25 |
Daily Volume: | 396,460 |
Market Cap: | US$1.410B |
May 09, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load